Abstracts tagged "interstitial lung disease"

Abstract Number: 0150 • ACR Convergence 2021
Clinical Characteristics and Quantitative CT Findings in Connective Tissue Disease-Associated Interstitial Lung Disease
Sirus Jesudasen¹, Badar Patel², Kristin D'Silva¹, Pietro Nardelli², Ruben San José Estépar², George Washko², Raúl San José Estépar², Farbod Rahaghi² and Sydney Montesi¹, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Precapillary Pulmonary Hypertension (PPH) is a known complication of connective tissue disease-associated interstitial lung disease (CTD-ILD) but at present requires right heart catheterization (RHC)…
Abstract Number: 0403 • ACR Convergence 2021
Effect of Nintedanib on KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
Shervin Assassi¹, Christopher Denton², Maurizio Cutolo³, Tracy Luckhardt⁴, Claudia Diefenbach⁵, Carina Ittrich⁶, Margarida Alves⁷ and Masataka Kuwana⁸, ¹University of Texas McGovern Medical School at Houston, Houston, TX, ²University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ³Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ⁴University of Alabama, Birmingham, AL, ⁵Boehringer Ingelheim Pharma GmBH, Biberach an der Riss, Germany, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁸Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Krebs von den Lungen-6 (KL-6), a marker of lung epithelial and endothelial injury, has been associated with progression of interstitial lung disease associated with…
Abstract Number: 0720 • ACR Convergence 2021
The Clinical Significance of anti-PC4 and SFRS1 Interacting Protein 1 Antibody in Polymyositis and Dermatomyositis Patients
Yuji Hosono¹, Azusa Kojima¹, Akira Ishii¹, Yuto Izumi¹, Kazuki Hirano¹, Noriko Sasaki², Chiho Yamada¹ and Shinji Sato³, ¹Tokai University School of Medicine, Isehara, Japan, ²tokai university, sagamihara-city, Japan, ³Tokai University, Isehara, Japan
Background/Purpose: Many kinds of myositis specific autoantibodies are detected in sera from polymyositis (PM) and dermatomyositis (DM). Screening for autoantibodies is essential in the diagnostic…
Abstract Number: 1453 • ACR Convergence 2021
Lung Interleukin-33 Is Elevated in Rheumatoid Arthritis-Associated Lung Disease
Rohit Gaurav¹, Ted Mikuls¹, Geoffrey Thiele¹, Bryant England¹, Madison Wolfe¹, Kristina Bailey¹, Amy Nelson¹, Michael Duryee¹, Debra Romberger¹, Dana Ascherman² and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The alarmin interleukin (IL)-33 is a member of the IL-1 cytokine family that is rapidly released from the nucleus of a variety of lung…
Abstract Number: 0176 • ACR Convergence 2021
Semi-quantitative Chest Computed Tomography (CT) Analysis in Pediatric Rheumatologic (PR) Patients with Diffuse Lung Disease
Michal Cidon¹, Terry Robinson², Beverley Newman³, Paul Iskander², Paul Thacker⁴, Evan Zucker³, Brian Bartholmai⁴, Dnyanesh Tipre², Tzielan Lee⁵, Rajdeep Pooni⁶ and Rex Moats², ¹Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital of Los Angeles, Los Angeles, CA, ³Stanford Children's Health, Stanford, ⁴Mayo Clinic, Rochester, MN, ⁵Stanford University School of Medicine, Palo Alto, CA, ⁶Stanford Children's Health, Palo Alto, CA
Background/Purpose: Spiral chest CT (SCT) is commonly used to evaluate subclinical lung disease in pediatric rheumatology. However, there are no validated scoring tools to objectively…
Abstract Number: 0408 • ACR Convergence 2021
A Histogram-based Densitometry Index to Support the Identification and the Assessment of Severity of Interstitial Lung Disease in Systemic Sclerosis: Applicability in Conventional and Low-dose Computed Tomography
COSIMO BRUNI¹, Alexandru Garaiman², Lorenzo Tofani³, Suzana Jordan⁴, Carmen-Marina Mihai⁴, Rucsandra Dobrota⁴, Muriel ELHAI⁵, Mike Oliver Becker⁴, Marco Matucci-Cerinic³ and Oliver Distler⁶, ¹University of Florence, Department of Rheumatology, Florence, Italy & Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Florence, Italy, ²University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³University of Florence, Florence, Italy, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁶Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland
Background/Purpose: High resolution computed tomography (conventional CT) represents the diagnostic gold standard for systemic sclerosis-related interstitial lung disease (SSc-ILD). A low-dose 9-slices (reduced) CT protocol…
Abstract Number: 0760 • ACR Convergence 2021
The Performance of RA Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis-Associated Interstitial Lung Disease in a Prospective Trial Using Pirfenidone in RA ILD (TRAIL1)
Paul Dellaripa¹, Tracy Doyle², Sonye Danoff³, Hillary Goldberg¹, Martin Kolb⁴, Daniel Chambers⁵, Felix Woodhead⁶, Cathy Spino⁷, Ivan Rosas⁸ and Joshua Solomon⁹, ¹Brigham and Women's, Boston, MA, ²Brigham and Women's Hospital, West Roxbury, MA, ³Johns Hopkins Medicine, Baltimore, MD, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Queensland, Brisbane St Lucia, Australia, ⁶University of Leicester, Leicester, United Kingdom, ⁷University of Michigan, Ann Arbor, MI, ⁸Baylor College of Medicine, Houston, TX, ⁹National Jewish Health, Denver, CO
Background/Purpose: Both rheumatoid arthritis (RA) and idiopathic pulmonary fibrosis (IPF) have established measures of disease severity and patient reported outcomes (PROs) that measure health-related quality…
Abstract Number: 1508 • ACR Convergence 2021
Decrease of Angiogenic T Cells Associated to the Presence of Interstitial Lung Disease in Patients with Connective Tissue Diseases
Verónica Pulito-Cueto¹, Sara Remuzgo-Martinez¹, Fernanda Genre¹, Belén Atienza-Mateo², Victor M. Mora-Cuesta³, David Iturbe-Fernández³, Leticia Lera-Gómez¹, Raquel Perez-Fernández¹, Pilar Alonso-Lecue⁴, Javier Rodriguez-Carrio⁵, Diana Prieto-Peña⁶, Virginia Portilla⁶, Ricardo BLANCO⁷, Alfosno Corrales⁶, José M. Cifrián⁸, Raquel López-Mejías¹ and Miguel Ángel gonzalez-Gay⁹, ¹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System; Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Deparment of Functional Biology, Immunology Area, Faculty of Medicine, Universidad de Oviedo, Oviedo, Asturias, Spain., Oviedo, Spain, ⁶Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Hospital University Marqués de Valdecilla, Santander, Spain, ⁸Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Pneumology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain, ⁹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Interstitial lung disease (ILD) is one of the most significant complications of connective tissue diseases (CTD) leading to an increase of the morbidity and…
Abstract Number: 0186 • ACR Convergence 2021
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases: Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Mueller⁶, Carl Coeck⁷, Klaus B Rohr⁸ and Wim A Wuyts⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, UK, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁷SCS Boehringer Ingelheim Comm.V., Brussels, Belgium, Brussels, Belgium, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis (IPF), nintedanib reduced the rate of decline in forced…
Abstract Number: 0409 • ACR Convergence 2021
Factors Predicting Mortality in an Indian Cohort of Systemic Sclerosis
T G Sundaram¹, Durga P Misra¹, Rudrarpan Chatterjee¹, Sakir Ahmed² and Vikas Agarwal³, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Kalinga Institute of Medical Sciences, Bhubaneswar, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Systemic sclerosis is characterised by high morbidity and mortality due to disease-related or treatment-related complications.Methods: Data of patients of systemic sclerosis between 1990 and…
Abstract Number: 0778 • ACR Convergence 2021
Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells in Patients with Treatment-Resistant Juvenile-Onset Systemic Sclerosis
Kathryn Torok¹, Franziska Rosser², Kirsten Rose-Felker¹, Vibha Sood¹, Geoffrey Kurland¹, Adam Olson¹, Meghan Frost¹, Vickie Vandergrift¹, Shawna McIntyre¹, Alisha Maslanka³, Kaila Schollaert-Fitch¹, Jessie Barnum¹ and Paul Szabolcs¹, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC Children's Hospital of Pittbsurgh, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is a rare autoimmune disease associated with life-threatening multi-organ inflammation and fibrosis. As in adults, jSSc organ involvement includes vascular,…
Abstract Number: 1629 • ACR Convergence 2021
Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease
Vivian Saper¹, Sampath Prahalad², Scott Canna³, Rabheh Abdul-Aziz⁴, Marcela Alvarez⁵, Catherine Bingham⁶, Brigitte Bader-Meunier⁷, Imelda Balboni⁸, Roberta Berard⁹, Roxana Bolaria¹⁰, Alexis Boneparth¹¹, Alicia Casey¹², Elaine Cassidy¹³, Joyce C. Chang¹⁴, Michal Cidon¹⁵, Kathleen Collins¹⁶, Aileen M. Dickenson¹⁷, Graciela Espada⁵, Martha Fishman¹², Elaine Flanagan¹⁸, Timothy Hahn¹⁹, Ankur K. Jindal²⁰, Ozgur Kasapcopur²¹, Marisa Klein-Gitelman²², Timothy Klouda¹², Mikhail Kostik²³, Carol Lake²⁴, Mariana Marques²⁵, Michael Ombrello²⁶, Karen Onel²⁷, Omkar Phadke²⁸, Angelo Ravelli²⁹, Adam Reinhardt³⁰, Amanda D. Robinson³¹, Kelly Rouster-Stevens³², Nadine Saad²⁷, Grant Schulert³³, Susan Shenoi³⁴, Cory Stingl¹⁴, Anjali Sura³⁵, Melissa Tesher³⁶, Jessica Tibaldi³⁷, Kathryn Torok³⁸, Cathy Tsin³⁹, Natalia Vasquez-Canizares⁴⁰, D. Sofia Villacis-Nunez⁴¹, Ben Whitehead⁴², Holly Wobma¹², Lawrence Zemel⁴³ and Elizabeth Mellins¹, ¹Stanford University, Stanford, CA, ²Emory + Children's Pediatric Institute, Atlanta, GA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴University at Buffalo, Buffalo, NY, ⁵Hospital de Niños Dr Ricardo Gutierrez, Buenos Aires, Argentina, ⁶Penn State Children's Hospital, Allentown, PA, ⁷Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, ⁸Stanford University, Palo Alto, CA, ⁹London Health Sciences Centre, London, ON, Canada, ¹⁰Self, Victoria, BC, Canada, ¹¹Columbia University Medical Center, New York, NY, ¹²Boston Children's Hospital, Boston, MA, ¹³University of Pittsburgh Medical Center Medical Education, Pittsburgh, PA, ¹⁴Children's Hospital of Phildelphia, Philadelphia, PA, ¹⁵Children's Hospital Los Angeles, Los Angeles, CA, ¹⁶LeBonheur Children's Hospital, Memphis, TN, ¹⁷Children's Hospital of Los Angeles, Los Angeles, CA, ¹⁸Emory University and Children's Healthcare of Atlanta, Atlanta, GA, ¹⁹Penn State Childrens Hospital, Hershey, PA, ²⁰Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey, ²²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁴National Institutes of Health, Gaithersburg, MD, ²⁵UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, ²⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²⁷Hospital for Special Surgery, New York, NY, ²⁸EMORY, Atlanta, GA, ²⁹Istituto Giannina Gaslini, Genoa, Italy, ³⁰Boys Town National Research Hospital, Omaha, NE, ³¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³⁴Seattle Children's Hospital, Seattle, WA, ³⁵SUNY Upstate Medical University, Syracuse, NY, ³⁶University of Chicago, Chicago, IL, ³⁷IRCSS Istituto G. Gaslini University of Genoa, Genoa, Italy, ³⁸University of Pittsburgh, Pittsburgh, PA, ³⁹Stanford University, Stanford, ⁴⁰Children's Hospital at Montefiore, Bronx, NY, ⁴¹Children's Healthcare of Atlanta - Emory University, Atlanta, GA, ⁴²Queensland Children's Hospital, Brisbane, Australia, ⁴³CCMC, Hartford, CT
Background/Purpose: Severe delayed hypersensitivity reactions (DHR) are under-recognized in inflammatory conditions, particularly drug reaction with eosinophilia and systemic symptoms (DRESS). Previous work has shown this…
Abstract Number: 0187 • ACR Convergence 2021
Safety and Tolerability of Nintedanib in Patients with Autoimmune Disease-Related Interstitial Lung Diseases: Pooled Data from the SENSCIS and INBUILD Trials
Vanessa Smith¹, Shervin Assassi², Yannick Allanore³, Lazaro Loaiza⁴, Inga Tschoepe⁵, Madhu Kanakapura⁴ and Elizabeth Volkmann⁶, ¹Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium, ²University of Texas McGovern Medical School at Houston, Houston, TX, ³Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁵Elderbrook Solutions, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁶Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The efficacy and safety of nintedanib have been investigated in patients with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial and in patients with…
Abstract Number: 0413 • ACR Convergence 2021
Predictors of ILD Development and Timing of Onset in Systemic Sclerosis: A Canadian Cohort
Jessica Kapralik, Robert Morton, Malik Farooqi, Karen Beattie, Nathan Hambly and Maggie Larche, McMaster University, Hamilton, ON, Canada
Background/Purpose: In patients with SSc, interstitial lung disease (SSc-ILD) and pulmonary hypertension affect 50-70% of patients and are the leading cause of death. Recent trials…
Abstract Number: 1014 • ACR Convergence 2021
Enhanced Expression of Rheumatoid Arthritis Related Autoantibodies Following Airborne Endotoxin Exposure in the Setting of Collagen-Induced Arthritis
Ted Mikuls¹, Rohit Gaurav¹, Geoffrey Thiele¹, Bryant England¹, Madison Wolfe¹, Brianna Shaw¹, Kristina Bailey¹, Amy Nelson¹, Michael Duryee¹, Carlos Hunter¹, Debra Romberger¹, Dana Ascherman² and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: In addition to inflammatory arthritis, collagen-induced arthritis (CIA) recapitulates cardinal features of rheumatoid arthritis (RA) including autoreactive T cells, peptidyl-arginine deiminase expression, and citrullination…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].